Vor Biopharma has rebounded from near-delisting by securing global rights (ex-China) to telitacicept, a promising autoimmune therapy. VOR's telitacicept targets multi-billion dollar autoimmune markets ...
Vor Biopharma Inc. (VOR) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, VOR's 50-day simple moving average crossed above its ...
Investor's Business Daily on MSN
Stocks to watch: Vor Biopharma sees RS rating jump to 89
On Wednesday, Vor Biopharma VOR hit a noteworthy technical benchmark, seeing its Relative Strength (RS) Rating jump into the 80-plus percentile with an improvement to 89, up from 62 the day before.
Vor Biopharma, a cancer cell therapy developer that laid off nearly all of its employees in a wind down of operations last month, has reemerged with new management, an in-licensed lead drug candidate, ...
Vor Bio announces a $55.6 million PIPE to fund clinical trials and expects to report updated data in 2025. Vor Bio, a clinical-stage cell and genome engineering company, announced a securities ...
Vor Biopharma Inc. (NASDAQ:VOR) shares are trading higher on Friday after the company announced it has entered into a securities purchase agreement for a private investment in public equity financing ...
Vor Biopharma (VOR) has jumped onto investors’ radar after strong Phase 3 data for telitacicept in IgA nephropathy, paired with upbeat new Wall Street coverage that frames the drug’s long term ...
New data from Vor Bio show that its hematopoietic stem cells have, so far, successfully engrafted in the first seven patients with relapsed or refractory acute myeloid leukemia and that the new cells ...
H.C. Wainwright upgraded Vor Biopharma Inc. (NASDAQ:VOR), highlighting the company’s “rebirth” following the in-licensing of telitacicept. On Thursday, the company announced a strategic licensing ...
Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...
Although VOR mostly focused on off-road motorcycles, it migrated to street bikes in 2002, the same year it changed its name to VOR Motorcycles. The VOR EN-E 530 is a big-bore four-stroke that ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vor Biopharma, a clinical-stage cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback